The Trump administration is moving to require the companies that manage hundreds of billions of dollars in drug spending to disclose details on how they get paid, according to a statement from the White House rapid response account.
New Transparency Mandate Targets Middlemen
The requirement targets the entities that sit between drug manufacturers and patients, often pharmacy benefit managers, which control massive prescription drug spending.
President Trump has long argued that hidden payment arrangements inflate the price Americans pay at the pharmacy counter. By forcing disclosure, the White House aims to expose rebates, fees, and other compensation that currently flow outside public view.
Hundreds of Billions Under New Scrutiny
The companies affected handle spending well into the hundreds of billions each year. That level of financial control has drawn repeated criticism from the administration, which contends that a lack of transparency lets middlemen profit while patients foot the bill.
"The Trump administration will require the companies that manage hundreds of billions of dollars of drug spending to disclose details on how they get paid," the White House rapid response team wrote in a social media post announcing the policy.
No additional specifics were included in the announcement, but the statement signals a clear regulatory shift. Industry groups have yet to respond publicly.
